SEC Form 4Coverage since Jul 23, 2026
$GLSI insider trading
Over the last 12 months, Greenwich LifeSciences insiders reported 3 buys totaling $97K and no sales across SEC Form 4 filings.
- Bought · 12m
- $97K 3 events
- Sold · 12m
- — 0 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $GLSI · 12Mvia TradingView
Top insiders · 12m
Patel SnehalCEO and CFO3× · $97K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Patel SnehalCEO and CFO · O·D·10% | ▲ Buy | 2,200 | $13.43 | $30K | — | 2 tranches |
| Jul 27, 2026 | Patel SnehalCEO and CFO · O·D·10% | ▲ Buy | 1,500 | $13.62 | $20K | — | — |
| Jul 24, 2026 | Patel SnehalCEO and CFO · O·D·10% | ▲ Buy | 3,600 | $13.06 | $47K | +0.1% | 2 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $GLSI feed.